Atlas Trials

Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma

Clinical trial NCT04714697 · UNKNOWN

Trial details

NCT number
NCT04714697
Sponsor
Asan Medical Center
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Renal Cell Cancer
Start date
2021-03-01
Primary completion
2023-02-28
Enrollment
201

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.